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OBJECTIVE — Glucagon-like peptide (GLP)-1 receptor is encoded by GLP1R. The effect of
genetic variation at this locus on the response to GLP-1 is unknown. This study assessed the
effectofGLP1Rpolymorphismsoninsulinsecretioninresponsetohyperglycemiaandtoinfused
GLP-1 in nondiabetic subjects.
RESEARCH DESIGN AND METHODS — Eighty-eight healthy individuals (aged 26.3 
0.6years,fastingglucose4.830.04mmol/l)werestudiedusingahyperglycemicclamp.GLP-1was
infused for the last2ho ft h estudy (0.75 pmol/kg/min over 121–180 min, 1.5 pmol/kg/min over
181–240 min). -Cell responsivity (Total) was measured using a C-peptide minimal model. The
effect of 21 tag single nucleotide polymorphisms (SNPs) in GLP1R on Total was examined.
RESULTS — Two SNPs (rs6923761 and rs3765467) were nominally associated with altered
-cell responsivity in response to GLP-1 infusion.
CONCLUSIONS — VariationinGLP1Rmayalterinsulinsecretioninresponsetoexogenous
GLP-1. Future studies will determine whether such variation accounts for interindividual dif-
ferences in response to GLP-1–based therapy.
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E
xpression of a nonsynonymous sin-
glenucleotidepolymorphism(SNP),
which results in substitution of me-
thionine for threonine at position 149 of
GLP1R in cell systems, decreases binding
afﬁnity for glucagon-like peptide (GLP)-1
andintracellularsignalingafterhormone-
receptor binding (1). These functional ef-
fects suggest that genetic variation in
GLP1RmayalterresponsivenesstoGLP-1
in vivo. To examine this hypothesis, we
used a hyperglycemic clamp, together
with GLP-1–amide (7,36) infusion, and
measured insulin secretion using a mod-
iﬁcation of the C-peptide minimal model
to determine -cell responsivity (Total)
to GLP-1 in vivo.
RESEARCH DESIGN AND
METHODS— Afterapprovalfromthe
Mayo Institutional Review Board, 88
healthy, nondiabetic subjects gave in-
formedwrittenconsenttoparticipate(on-
line appendix, available at http://care.
diabetesjournals.org/cgi/content/full/dc10-
0200/DC1). The study was registered at
www.clinicaltrials.gov (NCT00588380).
After an overnight fast, at 0700 (0
min)aprimed(0.1g/kgover4min),con-
tinuous infusion of 50% dextrose main-
tained peripheral glucose concentrations
at8.5mmol/l.At0900(120min),GLP-
1–amide (7,36) (Bachem, San Diego, CA)
was infused (1.5 pmol/kg over 10 min,
subsequently 0.75 pmol/kg/min). At
1000 (180 min), the infusion rate was in-
creased to 1.5 pmol/kg/min.
Measurement of insulin secretion:
C-peptide minimal model
The model used to describe -cell secre-
tion is a modiﬁcation of the C-peptide
minimal model that assumes a nonlinear
and derivative action of GLP-1 on both
the static (s) and dynamic (d) compo-
nents of total insulin secretion (Total)
(2,3).
Selection and genotyping of tag
SNPs for GLP1R
Twenty-one tag SNPs were genotyped
(online appendix).
Statistical analysis
All data are presented as means  SEM.
Using the Kruskal-Wallis (general allelic
model), we assessed univariate associa-
tions of genotype with Total in the pres-
ence of either glucose alone (mean values
at 110–120 min), or glucose and 0.75
pmol/kg/min GLP-1 (170–180 min), or
glucose and 1.5 pmol/kg/min GLP-1
(230–240 min), and with peak values of
Total observed in the presence of GLP-1.
IfthePvaluefortheoverallunivariatetest
of association was 0.1, then the associ-
ationsforspeciﬁcgenotypepairs(e.g.,1,1
vs. 1,2 or 2,2 vs. 1,1) were also examined
usingaMann-Whitneyranksumtest.The
SAS package was used for analyses, and a
P value 0.05 was considered to be sta-
tistically signiﬁcant.
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Effect of rs6923761 and rs3765467
genotype on -cell responsivity
Fig. 1A shows univariate association of
rs6923761 genotype with Total assum-
ing a general genetic model. At 120 min,
in the presence of glucose alone, no sig-
niﬁcant associations with Total were de-
tected (34  3 vs. 35  4 vs. 29  2
min
1, P  0.84) in the 1,1 (n  39)
versus the 1,2 (n  34) and 2,2 (n  14)
groups, respectively. At 180 min (low-
dose GLP-1), the associations with Total
also were not statistically signiﬁcant
(104  9 vs. 94  11 vs. 81  8 min
1,
P  0.11). The associations with Total at
240 min (high-dose GLP-1) were not sig-
niﬁcant (152  12 vs. 133  15 vs.
11210min
1,P0.10).Therewasno
association with peak values of Total
(160  12 vs. 143  17 vs. 119  10
min
1, P  0.09).
Whentheeffectofrs6923761genotype
on Total was examined (Fig. 1B) using a
recessive model (i.e., 1,1 vs. individuals
withoneormorecopiesoftheminorallele),
the associations at 240 min (152  12 vs.
127  11 min
1, P  0.03) and at peak
Total (160 12 vs. 136 12 min
1,P
0.03) were nominally signiﬁcant. Differ-
ences in Total at 180 min (104  9 vs.
90  8) were not signiﬁcant (P  0.09).
Thethreeheterozygotesfortheminor
allele of rs3765467 (Fig. 1C) exhibited
differences in Total at 120 min prior to
GLP-1 infusion (32  2 vs. 73  14
min
1, P  0.006), as well as in response
toGLP-1at180min(926vs.21935
min
1, P  0.005) and at 240 min
(132  7 vs. 325  44 min
1, P 
0.004). Nominally signiﬁcant associa-
tions at peak values of Total were also
observed (140  8 vs. 332  40 min
1,
P  0.005). An ANCOVA adjusting for
sex, BMI, and fasting glucose strength-
ened the association of rs3765467 with
peak and 240 min Total (P  0.0021,
P  0.0026, respectively). None of the
reported P values were corrected for mul-
tiple testing; applying a Benjamini-
Hochberg approach to correct for 21
SNPs and 3 measurements, a P value of
0.0024 would be signiﬁcant (4).
CONCLUSIONS — In this pilot
study, we show that in the presence of
hyperglycemia, two nonsynonymous
SNPs in GLP1R are nominally associated
with altered insulin secretory response to
infused GLP-1. One of these nonsynony-
mous SNPs, rs6923761 (which has a
minor allele frequency of 29% in Cau-
casians), results in the substitution of
serineforglycineatposition168andmay
decrease responsiveness to infused
GLP-1. Homozygotes for the major allele
of rs6923761 exhibited a 15% increase
Figure 1—Effect of rs6923761, analyzed with the general model (A), and with the recessive
model (B), and of rs3765467 (C)o nTotal in the presence and absence of GLP-1. *P  0.05.
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gotesorhomozygotesfortheminorallele.
The other nonsynonymous SNP,
rs3765467, results in substitution of glu-
tamine for arginine at position 131. Het-
erozygotes for the minor allele of
rs3765467 exhibited 100% increase in
Total compared with homozygotes for
the major allele. However, the observed
increaseinTotalinresponsetohypergly-
cemia alone suggests that these observa-
tions may not be solely due to altered
responsiveness to endogenous GLP-1.
The actions of GLP-1 (primarily stim-
ulation of insulin secretion and suppres-
sion of glucagon secretion) are mediated
by binding to its cognate receptor. Ex-
enatide, a GLP-1 receptor agonist, binds
totheGLP-1receptorwithgreaterafﬁnity
than its natural ligand due to a nine ami-
no-acid COOH-terminal sequence that is
absent in native GLP-1 (5). Substitution
of glycine for alanine at position eight of
native GLP-1 decreases afﬁnity for the re-
ceptor (6), suggesting that both N- and
COOH-terminal ends of GLP-1 bind the
receptor.
A consequence of the constant glu-
cose concentrations during the experi-
ment was that d was a small component
of Total; prior studies have suggested
that incretins alter both static and dy-
namic components of -cell responses
(7,8). GLP-1 also inhibits gastrointestinal
motility and may alter glucose delivery to
the small intestine (9). By design, our ex-
periment could not test for any potential
effects of variation in GLP1R on these pa-
rameters. At present, variation in GLP1R
has not been associated with type 2 dia-
betes (10); together with the data in our
study, this suggests that genetic differ-
ences in GLP-1 responsiveness attribut-
able to variation in GLP1R likely occurs at
supraphysiologic GLP-1 concentrations.
Given the exploratory nature of this ex-
periment, the results should be inter-
preted cautiously prior to replication in
othercohortswithanincreasedfrequency
of the minor allele of rs3765467.
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